Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Laux

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Journal of Psychiatric Research|October 27, 2004
Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controlsMichael Soyka, Catja Winter, Sabine Kagerer, et al.
Psychiatry Research|June 14, 2011
Cannabinoids improve driving ability in a Tourette's patientAlexander Brunnauer, Felix Maximilian Segmiller, Thomas Volkamer, et al.
The Journal of Clinical Psychiatry|February 11, 2009
The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patientsAlexander Brunnauer, Gerd Laux, Irmgard David, et al.
Therapeutic Drug Monitoring|June 7, 2013
Quetiapine and norquetiapine serum concentrations and clinical effects in depressed patients under augmentation therapy with quetiapineElnaz Ostad Haji, Stefanie Wagner, Mirijam Fric, et al.
European Archives of Psychiatry and Clinical Neuroscience|October 27, 2015
Driving skills in unmedicated first- and recurrent-episode schizophrenic patientsFelix M Segmiller, Verena Buschert, Gerd Laux, et al.
Journal of Clinical Pharmacology|February 22, 2013
Driving ability according to German guidelines in stabilized bipolar I and II outpatients receiving lithium or lamotrigineFelix M Segmiller, Igor Hermisson, Michael Riedel, et al.
Acta Psychiatrica Scandinavica|November 3, 2020
Combining machine learning algorithms for prediction of antidepressant treatment responseAlexander Kautzky, Hans-Juergen Möller, Markus Dold, et al.
Therapeutic Drug Monitoring|May 14, 2013
Potential cost-effectiveness of therapeutic drug monitoring for depressed patients treated with citalopramElnaz Ostad Haji, Klaus Mann, Aleksandra Dragicevic, et al.
Pharmacopsychiatry|September 21, 2018
Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled StudyRebecca Schennach, Michael Riedel, Ilja Spellmann, et al.
BMC Psychiatry|May 22, 2016
Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatientsFlorian Seemüller, Michael Obermeier, Rebecca Schennach, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Journal of Psychiatric Research|October 27, 2004
Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controlsMichael Soyka, Catja Winter, Sabine Kagerer, et al.
Psychiatry Research|June 14, 2011
Cannabinoids improve driving ability in a Tourette's patientAlexander Brunnauer, Felix Maximilian Segmiller, Thomas Volkamer, et al.
The Journal of Clinical Psychiatry|February 11, 2009
The impact of reboxetine and mirtazapine on driving simulator performance and psychomotor function in depressed patientsAlexander Brunnauer, Gerd Laux, Irmgard David, et al.
Therapeutic Drug Monitoring|June 7, 2013
Quetiapine and norquetiapine serum concentrations and clinical effects in depressed patients under augmentation therapy with quetiapineElnaz Ostad Haji, Stefanie Wagner, Mirijam Fric, et al.
European Archives of Psychiatry and Clinical Neuroscience|October 27, 2015
Driving skills in unmedicated first- and recurrent-episode schizophrenic patientsFelix M Segmiller, Verena Buschert, Gerd Laux, et al.
Journal of Clinical Pharmacology|February 22, 2013
Driving ability according to German guidelines in stabilized bipolar I and II outpatients receiving lithium or lamotrigineFelix M Segmiller, Igor Hermisson, Michael Riedel, et al.
Acta Psychiatrica Scandinavica|November 3, 2020
Combining machine learning algorithms for prediction of antidepressant treatment responseAlexander Kautzky, Hans-Juergen Möller, Markus Dold, et al.
Therapeutic Drug Monitoring|May 14, 2013
Potential cost-effectiveness of therapeutic drug monitoring for depressed patients treated with citalopramElnaz Ostad Haji, Klaus Mann, Aleksandra Dragicevic, et al.
Pharmacopsychiatry|September 21, 2018
Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled StudyRebecca Schennach, Michael Riedel, Ilja Spellmann, et al.
BMC Psychiatry|May 22, 2016
Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatientsFlorian Seemüller, Michael Obermeier, Rebecca Schennach, et al.
Pageof 10